Neoadjuvant Intralesional Targeted Immunocytokines (Daromun) in Stage III Melanoma
{{output}}
Background: This phase 3 trial assessed daromun, a combination of two fibronectin-targeting immunocytokines (L19IL2 and L19TNF), as a neoadjuvant treatment for patients with clinically detectable stage IIIB/C melanoma (AJCC versi... ...
